Latest News and Press Releases

Revenue scaled ahead of plan; Q1 revenue of $3.0 million, up 238% sequentially and 578% year over year, reflecting growth across all offerings. Entered into additional vertical through acquisition...

Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for...

TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027TX2100 advanced into Phase 1a healthy volunteer clinical trial...

Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026Five additional Phase 3 studies of azetukalner continue to enroll in...

$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial...

- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - -...

Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress,...

Akamai reports first quarter 2026 financial results.

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing...

FDA approved AVLAYAH™ (tividenofusp alfa-eknm) for treatment of Hunter syndrome (MPS II) and as first medicine to leverage transferrin receptor to cross blood-brain barrierAVLAYAH launched in U.S....